再度活跃!中烟香港(6055.HK)连续第三日上涨 累涨25%
格隆汇9月3日丨8月26日晚间公布中报的中烟香港(6055.HK)随后连续3日下跌,一度累跌23.6%,之后又出现明显反弹,至今已连涨3日,累涨25%,现报23.75港元,相较于今年6月上市时4.88港元的IPO价格,上市3个月不到,目前股价已溢价386%,最新总市值165亿港元,最新动态市盈率高达80倍。此前有分析人士对格隆汇表示,中烟香港的问题不在于业绩,因影响上半年业绩的中美贸易摩擦和人民币贬值两大因素都是短期因素,即便下半年不能马上好转,长期来看这两大因素都不是问题,公司真正的问题在于目前的估值过高,而稀缺性能否支撑其高估值,只能拭目以待了。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.